• CSO of a biotechnology company, provide guidance and leadership in formulating research direction, determining feasibility and stratifying importance of initiatives for developing exosome-based diagnostic assays targeting oncology and therapeutic monitoring. • For 3 decades, since publishing the discovery of circulating exosomes, developed genomic, proteomic and metabolomic technologies to define stable, specific markers detecting cancer presence, defining tumor characteristics, and predicting cancer risk, correlating these with molecular characteristics and real-time clinical parameters ("liquid biopsy”). • Served on the SAB for multiple industrial companies established objectives for technology development and cancer diagnosis research programs; including organizing efforts to initiate pioneering technology and programs and to address issues involving policy pertaining to exosome-based diagnosis research• Significant experience and knowledge of intellectual property management, including technology transfer and university-industry relations. Based on the clinical applications of my work, gained significant expertise into the area of clinical regulatory issues.